BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29935840)

  • 1. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
    Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
    Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
    Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
    Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma.
    Li JR; Ou YC; Yang CK; Wang SS; Chen CS; Ho HC; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Hung SC; Hsu CY; Chiu KY
    Anticancer Res; 2018 Sep; 38(9):5339-5345. PubMed ID: 30194186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
    Culp SH; Karam JA; Wood CG
    Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
    Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
    J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
    You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.
    Yu X; Wang B; Li X; Lin G; Zhang C; Yang Y; Fang D; Song Y; He Z; Zhou L
    Biomed Res Int; 2015; 2015():176373. PubMed ID: 26568955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
    Karam JA; Rini BI; Varella L; Garcia JA; Dreicer R; Choueiri TK; Jonasch E; Matin SF; Campbell SC; Wood CG; Tannir NM
    J Urol; 2011 Feb; 185(2):439-44. PubMed ID: 21167518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.